Sebode M - Search Results

1

Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care.

Rüther DF, Weltzsch JP, Schramm C, Sebode M, Lohse AW. Rüther DF, et al. Among authors: sebode m. J Hepatol. 2022 Jul;77(1):250-251. doi: 10.1016/j.jhep.2022.02.013. Epub 2022 Mar 10. J Hepatol. 2022. PMID: 35282896 Free PMC article. No abstract available.

2

FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency.

Peiseler M, Sebode M, Franke B, Wortmann F, Schwinge D, Quaas A, Baron U, Olek S, Wiegard C, Lohse AW, Weiler-Normann C, Schramm C, Herkel J. Peiseler M, et al. Among authors: sebode m. J Hepatol. 2012 Jul;57(1):125-32. doi: 10.1016/j.jhep.2012.02.029. Epub 2012 Mar 14. J Hepatol. 2012. PMID: 22425700

3

[Inflammatory diseases with liver and joint involvement. A differential diagnostic challenge].

Sebode M, Schramm C, Lohse AW. Sebode M, et al. Internist (Berl). 2013 Apr;54(4):441-8. doi: 10.1007/s00108-012-3191-6. Internist (Berl). 2013. PMID: 23455625 German.

4

Autoimmune hepatitis 2013 and beyond.

Weiler-Normann C, Sebode M, Lohse AW. Weiler-Normann C, et al. Among authors: sebode m. Minerva Gastroenterol Dietol. 2013 Jun;59(2):133-41. Minerva Gastroenterol Dietol. 2013. PMID: 23831905

5

Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms.

Sebode M, Peiseler M, Franke B, Schwinge D, Schoknecht T, Wortmann F, Quaas A, Petersen BS, Ellinghaus E, Baron U, Olek S, Wiegard C, Weiler-Normann C, Lohse AW, Herkel J, Schramm C. Sebode M, et al. J Hepatol. 2014 May;60(5):1010-6. doi: 10.1016/j.jhep.2013.12.027. Epub 2014 Jan 8. J Hepatol. 2014. PMID: 24412607

6

Future perspective: immunomodulatory therapy for autoimmune hepatitis.

Sebode M, Lohse AW. Sebode M, et al. Dig Dis. 2014;32(5):502-6. doi: 10.1159/000360493. Epub 2014 Jul 14. Dig Dis. 2014. PMID: 25034282 Review.

7

Phenotypic alterations of regulatory T cells in autoimmune hepatitis: causal or associated with treatment and remission?

Sebode M, Peiseler M, Weiler-Normann C, Schramm C, Lohse AW, Herkel J. Sebode M, et al. Hepatology. 2015 Feb;61(2):736-7. doi: 10.1002/hep.27301. Epub 2015 Jan 5. Hepatology. 2015. PMID: 25044332 No abstract available.

8

New foe treated with old guns - supportive role of steroids in the treatment of acute severe hepatitis E.

Sebode M, Pischke S, Lütgehetmann M, Polywka S, Quaas A, Lohse AW, Wege H. Sebode M, et al. BMC Gastroenterol. 2014 Nov 15;14:191. doi: 10.1186/s12876-014-0191-0. BMC Gastroenterol. 2014. PMID: 25398314 Free PMC article.

9

Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis.

Hartl J, Ehlken H, Weiler-Normann C, Sebode M, Kreuels B, Pannicke N, Zenouzi R, Glaubke C, Lohse AW, Schramm C. Hartl J, et al. Among authors: sebode m. J Hepatol. 2015 Mar;62(3):642-6. doi: 10.1016/j.jhep.2014.10.018. Epub 2014 Oct 18. J Hepatol. 2015. PMID: 25457202

10

Natural killer T cells: novel players in biliary disease?

Sebode M, Schramm C. Sebode M, et al. Hepatology. 2015 Oct;62(4):999-1000. doi: 10.1002/hep.27862. Epub 2015 Jun 3. Hepatology. 2015. PMID: 25914184 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters